Table 6.1

Placebo controlled trials of mesalazine for maintenance of medically induced remission in Crohn’s disease

Author	Year	Number of patients	Dose (g/j)	Duration (months)	Relapse rate (%)			Comments	Ref section 2
Author	Year	Number of patients	Dose (g/j)	Duration (months)	5-ASA	Placebo	p Value	Comments	Ref section 2
IMSG, International Mesalazine Study Group; I, ileal; C, colonic. *Remission <3 months.
IMSG*	1990	248	1.5	12	8.3	31	0.05		106
Bondesen	1991	202	3	12–18	29	29	NS		107
Bresci	1991	38	1.6	36	80	94	NS		108
Brignola	1992	44	2	4	52	59	NS		104
Prantera	1992	125	2.4	12	34	55	0.02		109
Gendre	1993	161	2	24	47	42	NS	low risk	110
					55	71	<0.003	high risk*
Arber	1995	59	1	12	27	55	<0.05		111
Thomson	1995	286	3	12	27	31	NS	I + C	112
					40	26	NS	I
Modigliani	1996	129	4	12	62	64	0.05*	*for corticosteroid weaning	113
De Franchis	1997	117	3	12	58	52	NS		114
Sutherland	1997	293	3	11.5	25	36	NS		115
					21	41	0.02	I + C
Mahmud	2001	328	2	12	48	45	NS		116